title: Cox-2 in non-small cell lung cancer: a meta-analysis.
abstract: BACKGROUND
  We investigated the prognostic value of cyclooxygenase-2 (COX-2) for survival of patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  We performed a meta-analysis of literature to aggregate the available survival results, using studies published in English until June 2012. Eligible studies dealt with COX-2 protein assessment in NSCLC patients on primary lesions and reported survival data according to COX-2 expression.
  
  
  RESULTS
  Nineteen trials, comprising 2651 patients, provided sufficient information for the meta-analysis. Overall combined hazard ratio (HR) was 1.86 (95% CI: 1.58-2.20); it was calculated using a random-effects model, and associates high COX-2 expression with poor survival in all NSCLC patients. Aggregate survival data showed poor survival for patients with adenocarcinoma (ADC), squamous cell cancer (SCC) and Stage I NSCLC with high COX-2 expression, at 2.00 (95% CI: 1.38-2.88), 2.29 (95% CI: 1.58-3.33) and 1.95 (95% CI: 1.31-2.91) respectively.
  
  
  CONCLUSIONS
  Our meta-analysis shows that the COX-2 expression status is an independent prognostic factor in NSCLC, and this tendency applies to SCC, ADC and stage I NSCLC.
authors: Department of Geriatric Oncology, the Second Affiliated Hospital, Southeast University, Nanjing, Jiangsu 210003, PR China. gfdsa_1234567@sohu.com
authors: Hao
authors: H
authors: Jiang
authors: Jing
authors: J
authors: Wang
authors: Wei
authors: W
authors: Zhao
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis*; D051546:Cyclooxygenase 2 / Q000032:analysis* / Q000096:biosynthesis; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis*; D011379:Prognosis; D016016:Proportional Hazards Models; D015996:Survival Rate
chemical_list: D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human